Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hengrui Out-Licenses its PD-1 for Liver Cancer to Elevar in $1 Billion Deal

publication date: Oct 18, 2023

Jiangsu Hengrui Medicine out-licensed global rights (ex-China) for its anti-PD-1 antibody to New Jersey’s Elevar Therapeutics in a $1 billion deal. Elevar will have rights to commercialize Hengrui’s camrelizumab in combination with Elevar’s rivoceranib for unresectable hepatocellular carcinoma (uHCC) worldwide. The two companies partnered clinical development of the pairing in the US, filing a BLA in May of this year. Elevar will pay Hengrui Pharma up to $600 million in sales milestones and a double-digit percentage royalty, bringing the 10-year payout up to $1 billion. More details....

Stock Symbol: (SHA: 600275)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital